Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis
DOI:
https://doi.org/10.47957/ijciar.v7i2.176Keywords:
Mirikizumab, ulcerative colitis, monoclonal antibodies, inflammatory diseaseAbstract
A monoclonal antibody called mirikizumab is used to treat ulcerative colitis. It is marketed under the Omvoh brand. It is intended to bind to interleukin-23 (IL-23) and obstruct its function. Upper respiratory tract (nose and throat) infections, headaches, rashes, and injection site responses (when administered by subcutaneous injection) are the most frequent adverse effects. In the United States in October 2023 and the European Union in May 2023, mirikizumab was authorized for medicinal use. For the treatment of people with moderately to highly active ulcerative colitis who have not responded well to, have lost responsiveness to, or are intolerant to either biologic therapy or conventional therapy, mirikizumab is suggested. A subset of people with ulcerative colitis (UC) do not react to currently available medications, despite advancements in UC medical therapy. Many innovative medications have recently acquired regulatory approval for use in UC, or are in the latter stages of development. The novel antibody mirikizumab, which is given intravenously (IV), binds to the inflammatory protein interleukin 23 and inhibits its function, preventing inflammation from being triggered. For individuals with moderately to highly active UC, mirikizumab would therefore provide an additional therapy choice if legalized.
Downloads
References
Hwisa NT, Gindi S, Chandu BR, Katakam P. Evaluation of Antiulcer Activity of Picrasma quassioides (D. Don) Bennett Aqueous Extract in Rodents.
Turner D, Ricciuto A, Lewis A, D’amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021 Apr 1;160(5):1570-83. DOI: https://doi.org/10.1053/j.gastro.2020.12.031
Sumalatha G, Awen BZ, Chandu B, Mukkanti K. Anti ulcerogenic & ulcer healing studies of aqueous extract of Pueraria tuberosa leaves on rats. International Journal of Pharma and Bio Sciences. 2010;1(4).
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine. 2013 Aug 22;369(8):699-710. DOI: https://doi.org/10.1056/NEJMoa1215734
Gindi S, Methra T, Chandu BR, Boyina R, Dasari V. Antiurolithiatic and invitro anti-oxidant activity of leaves of Ageratum conyzoides in rat. World J Pharm Pharm Sci. 2013 Feb 8;2:636-49.
Sands BE, Sandborn WJ, Panaccione R, O’Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S. Ustekinumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine. 2019 Sep 26;381(13):1201-14. DOI: https://doi.org/10.1056/NEJMoa1900750
Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to anti-TNFs: definition, epidemiology, and management. Clinical and translational gastroenterology. 2016 Jan 1;7(1):e135. DOI: https://doi.org/10.1038/ctg.2015.63
Singh JA, Wells GA, Christensen R, Ghogomu ET, Maxwell LJ, MacDonald JK, Filippini G, Skoetz N, Francis DK, Lopes LC, Guyatt GH. Adverse effects of biologics: a network meta‐analysis and Cochrane overview. Cochrane database of systematic reviews. 2011(2). DOI: https://doi.org/10.1002/14651858.CD008794
Hwisa NT, Gindi S, Rao CB, Katakam P, Rao Chandu B. Evaluation of Antiulcer Activity of Picrasma Quassioides Bennett Aqueous Extract in Rodents. Vedic Res. Int. Phytomedicine. 2013;1:27. DOI: https://doi.org/10.14259/pm.v1i1.35
Sandborn WJ, Baert F, Danese S, Krznarić Ž, Kobayashi T, Yao X, Chen J, Rosario M, Bhatia S, Kisfalvi K, D’Haens G. Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology. 2020 Feb 1;158(3):562-72. DOI: https://doi.org/10.1053/j.gastro.2019.08.027
Schreiber S, Ben-Horin S, Leszczyszyn J, Dudkowiak R, Lahat A, Gawdis-Wojnarska B, Pukitis A, Horynski M, Farkas K, Kierkus J, Kowalski M. Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease. Gastroenterology. 2021 Jun 1;160(7):2340-53. DOI: https://doi.org/10.1053/j.gastro.2021.02.068
Bots SJ, Parker CE, Brandse JF, Löwenberg M, Feagan BG, Sandborn WJ, Jairath V, D’Haens G, Vande Casteele N. Anti-drug antibody formation against biologic agents in inflammatory bowel disease: a systematic review and meta-analysis. BioDrugs. 2021 Nov;35:715-33. DOI: https://doi.org/10.1007/s40259-021-00507-5
Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000 Nov 1;13(5):715-25. DOI: https://doi.org/10.1016/S1074-7613(00)00070-4
Moschen AR, Tilg H, Raine T. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nature Reviews Gastroenterology & Hepatology. 2019 Mar;16(3):185-96. DOI: https://doi.org/10.1038/s41575-018-0084-8
Patel DD, Kuchroo VK. Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions. Immunity. 2015 Dec 15;43(6):1040-51. DOI: https://doi.org/10.1016/j.immuni.2015.12.003
Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003 Jan 1;52(1):65-70. DOI: https://doi.org/10.1136/gut.52.1.65
Becker C, Dornhoff H, Neufert C, Fantini MC, Wirtz S, Huebner S, Nikolaev A, Lehr HA, Murphy AJ, Valenzuela DM, Yancopoulos GD. Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. The Journal of Immunology. 2006 Sep 1;177(5):2760-4. DOI: https://doi.org/10.4049/jimmunol.177.5.2760
O'Connor Jr W, Kamanaka M, Booth CJ, Town T, Nakae S, Iwakura Y, Kolls JK, Flavell RA. A protective function for interleukin 17A in T cell–mediated intestinal inflammation. Nature immunology. 2009 Jun;10(6):603-9. DOI: https://doi.org/10.1038/ni.1736
Uhlig HH, McKenzie BS, Hue S, Thompson C, Joyce-Shaikh B, Stepankova R, Robinson N, Buonocore S, Tlaskalova-Hogenova H, Cua DJ, Powrie F. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity. 2006 Aug 1;25(2):309-18. DOI: https://doi.org/10.1016/j.immuni.2006.05.017
Langley RG, Tsai TF, Flavin S, Song M, Randazzo B, Wasfi Y, Jiang J, Li S, Puig L. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial. British Journal of Dermatology. 2018 Jan 1;178(1):114-23. DOI: https://doi.org/10.1111/bjd.15750
Published
How to Cite
Issue
Section
Citations
This work is licensed under a Creative Commons Attribution 4.0 International License.
